← The Wire
PALINasdaq
PALISADE BIO, INC.
Biological Products, (No Diagnostic Substances) · DE · CIK 1357459
Developing targeted oral PDE4 inhibitor prodrugs for inflammatory bowel disease
red 8-K · 90d
$297M
Market cap
$2.23
Last close
+18.0%
1D
+21.2%
5D
11.2M
Volume
Price · last 39 sessions+4.7%
May 4L $1.68 · H $2.23Jun 29
485
Total filings
Jun 11, 2026
Last filing
12/31
Fiscal year end
8-KExecutive Change · Bylaw AmendmentJun 11, 20268-KResults of OperationsMay 12, 202610-Q10-QMay 12, 2026DEFA14ADEFA14AApr 29, 2026DEF 14ADEF 14AApr 29, 20268-KCompany UpdateApr 2, 202610-K10-KMar 20, 20268-KBylaw Amendment · Shareholder VoteDec 4, 202510-Q10-QNov 10, 2025DEFA14ADEFA14ANov 3, 2025DEF 14ADEF 14AOct 28, 20258-KExecutive ChangeOct 22, 20258-KShareholder VoteOct 20, 20258-KCompany UpdateOct 16, 20258-KCompany UpdateOct 9, 2025DEFA14ADEFA14AOct 7, 2025424B4424B4Oct 2, 2025S-1S-1Sep 29, 20258-KCompany UpdateSep 26, 20258-KCompany UpdateSep 18, 2025DEF 14ADEF 14ASep 15, 2025DEFA14ADEFA14ASep 15, 20258-KExecutive ChangeSep 5, 2025DEF 14ADEF 14AAug 18, 202510-Q10-QAug 11, 20258-KMaterial Agreement · Equity IssuanceJul 25, 20258-KExecutive Change · Company UpdateJul 9, 2025S-1S-1May 27, 202510-Q10-QMay 12, 20258-KDelisting NoticeMay 2, 202510-K10-KMar 24, 20258-KMaterial Agreement · Equity IssuanceDec 16, 2024424B5424B5Dec 13, 2024S-1/AS-1/ADec 9, 2024S-1/AS-1/ADec 5, 2024S-1/AS-1/ANov 21, 2024SC 13GSC 13GNov 14, 202410-Q10-QNov 12, 2024S-1S-1Oct 30, 20248-KExecutive Change · Material AgreementSep 27, 202410-Q10-QAug 12, 20248-KShareholder VoteJul 8, 2024DEFA14ADEFA14AMay 22, 2024DEF 14ADEF 14AMay 22, 202410-Q10-QMay 13, 20248-KExecutive Change · Company UpdateMay 10, 20248-KMaterial Agreement · Equity IssuanceMay 3, 20248-KCompany UpdateApr 10, 20248-KBylaw Amendment · Company UpdateApr 5, 20248-KDelisting Notice · Results of OperationsMar 27, 202410-K10-KMar 26, 20248-KExecutive Change · Bylaw AmendmentMar 6, 20248-KExecutive Change · Company UpdateFeb 13, 2024DEFA14ADEFA14AFeb 6, 2024DEF 14ADEF 14AFeb 6, 20248-KMaterial Agreement · Equity IssuanceFeb 1, 20248-KReg FD DisclosureJan 29, 2024S-1S-1Dec 29, 202310-Q10-QNov 9, 20238-KReg FD DisclosureNov 7, 20238-KDelisting NoticeOct 20, 2023SC 13GSCHEDULE 13GSep 15, 2023SC 13GSC 13GSep 15, 20238-KExecutive Change · Material AgreementSep 11, 20238-KMaterial Agreement · Equity IssuanceSep 11, 2023424B5424B5Sep 11, 20238-KMaterial Agreement · Acquisition / DispositionSep 8, 202310-Q10-QAug 10, 20238-KExecutive Change · Material AgreementJun 9, 202310-Q10-QMay 11, 2023S-1/AS-1/AApr 27, 2023S-1S-1Apr 21, 2023DEFA14ADEFA14AApr 21, 2023DEF 14ADEF 14AApr 21, 20238-KMaterial Agreement · Equity IssuanceApr 5, 2023424B5424B5Apr 5, 202310-K10-KMar 22, 20238-KCompany UpdateMar 13, 2023SC 13GSC 13GFeb 14, 20238-KExecutive Change · Equity IssuanceFeb 8, 2023
Insider Activity
In the 90 days to Feb 12, 2026: 1 insider bought $18K · 2 sold $10K.
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| Feb 12, 2026 | Finley John DavidCEO, CFO | Sell | 3,896 | $1.75 | $7K |
| Feb 12, 2026 | Jones Mitchell LawrenceChief Medical Officer | Sell | 1,989 | $1.75 | $3K |
| Jan 16, 2026 | Williams Donald AllenDirector | Buy | 5,000 | $1.67 | $8K |
| Jan 9, 2026 | Williams Donald AllenDirector | Buy | 5,000 | $1.88 | $9K |
Open-market buys & sells (Form 4, transaction codes P/S). Source: SEC structured insider data.
Similar companies
Comparable business profile · signals at a glance